Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Christos C. Zouboulis, Amit Garg, Christopher J. Sayed, Gregor Jemec, Georgios Kokolakis, John R. Ingram, Akimichi Morita, Pratiksha Dokhe, Ingrid Pansar, Robert Rolleri, Christina Crater, Asim Datye, Alexa B. Kimball
Fingerprint
Dive into the research topics of 'Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT'. Together they form a unique fingerprint.
Keyphrases
Agricultural and Biological Sciences
Pharmacology, Toxicology and Pharmaceutical Science